Opinion|Videos|June 14, 2024
Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from non-relapsing forms (non-relapsing secondary progressive) in clinical practice, and highlight the key pathophysiological features of relapsing multiple sclerosis and the impact of progression independent of relapse activity (PIRA) after an initial demyelinating event.
Advertisement
Episodes in this series
- Patients with MS typically experience significant clinical impact. How does the disease impact patients, as well as their families and other caregivers?
- How are relapsing forms of MS (eg, RELAPSING MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS) differentiated in clinical practice from non-relapsing forms (non-relapsing secondary progressive multiple sclerosis)?
- What are the key features of the pathophysiology of RELAPSING MULTIPLE SCLEROSIS and the impact of progression independent of relapse activity (PIRA) after a first demyelinating
event ? - What are the hallmark features of non-relapsing secondary progressive multiple sclerosis and what is the prevalence of non-relapsing secondary progressive multiple sclerosis seen in clinical practice?
Advertisement
Related to this article
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5